Evidence map›Paper›PMID 25214894›Full record

ArticleBreast cancer management2014

Understanding susceptibility to breast cancer metastasis: the genetic approach.

Anjali Shukla, Jude Alsarraj, Kent Hunter

Open access · greenAbstract read
In one paragraph

Article in Breast cancer management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Metastasis as a systemic disease: molecular insights and clinical implications.Biochimica et biophysica acta. Reviews on cancer · 2019
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Anjali ShuklaLaboratory of Cancer Biology & Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Jude AlsarrajLaboratory of Cancer Biology & Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Kent HunterLaboratory of Cancer Biology & Genetics, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Center for Cancer Research · USNational Cancer Institute · US

Funding

Genetic Modifiers of Intitiation and Progression of Mammary CancerZIABC011255 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HUNTER, KENT WILLIAM · 2010 to 2025
$33.2M
GENETIC MODIFIERS OF MAMMARY CANCER INITIATION/ PROGRESSZ01CP010146 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI HUNTER, KENT WILLIAM · 2000 to 2008
$3.3M
Intramural NIH HHS Z01 CP010146Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011255
6 · The paper itself

Abstract

Metastasis is a complex phenotype that is not discrete, is polygenic, varies in range over the entire population and follows non-Mendelian inheritance. Recent evidence indicates that inherited susceptibility affects not only the development of the primary tumor, but is also an important factor in progression and metastasis. Since metastasis accounts for the majority of breast cancer deaths, identification and understanding of the genetic modifiers of metastasis underlies success of personalized therapy. Studies from our laboratory and others have now characterized several metastasis susceptibility factors. While an important step forward, these certainly do not describe the entire metastatic phenomenon and efforts continue to expand this knowledge. Here we review the complex metastatic process and current knowledge on the genetics of breast cancer metastasis, including germline polymorphisms that have been associated with the disease.

Identifiers

PMID25214894
PMCPMC4157690
OpenAlexW2130909992

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.